EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 20:58 (681 d 13:36 ago) – Posting: # 20959
Views: 4,627

Dear Osama,

» I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,
Mittyri

Complete thread:

Activity
 Admin contact
21,739 posts in 4,546 threads, 1,543 registered users;
online 5 (0 registered, 5 guests [including 1 identified bots]).
Forum time: Tuesday 11:34 CEST (Europe/Vienna)

Sometimes the key to an answer is found
in the way you formulate the question.    David Brin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5